Cancer projectsBreast cancer risk screening. This initiative will reduce unnecessary hospital referrals, saving costs, plus increase access to screening in the community for patients. Using innovative software – called ‘Family History Risk Assessment Software’ (FaHRAS) – the project will assist GP’s in determining a person’s likelihood of developing breast cancer, and any requirement for a secondary care assessment, within the primary care settings.
Previously only available in hospitals once patients have already been referred, the software will be available in doctors’ surgeries initially in parts of Lincolnshire and Nottinghamshire. The FaHRAS tool has been proven to improve levels of detection for patients who need it most whilst significantly reducing numbers of inappropriate referrals to specialist hospital-based services.
Improving post cancer diagnosis outcomes for patients. This project will support healthcare professionals, including NHS, social care and third-sector carers, to provide seamless care for people who have a new cancer diagnosis. It focuses on implementing the Holistic Needs Assessment (HNA) tool (which is a national requirement), but in a consistent electronic format. This is the first time the tool will be available electronically, enabling rapid sharing with all parties involved in care of the patient. It provides patients with the opportunity to complete the assessment themselves using an iPad or supported by a healthcare professional.
The assessment can take place in community or hospital settings and will help provide improved planning and delivery of care services. Patients can identify unmet needs, such as pain management, and the tool should improve quality of life for many people.
Initially the eHNA will roll out in Nottinghamshire by Nottingham University Hospitals NHS Trust working with Macmillan Cancer Support in conjunction with local Clinical Commissioning Groups (CCGs) and other care providers.
Moving therapy for bone metastases in cancer patients into the community. This innovation focusses upon moving the administration of denosumab (XGEVA®), a NICE-recommended drug therapy for people with advanced cancer, from a hospital setting into the community.
On average it will save £58 per administration of the drug and will bring care closer to home for many patients across the East Midlands. It will also help to free up capacity in hospital oncology departments. The project is being supported by Amgen Ltd. and builds upon work already undertaken by Amgen Ltd., University Hospitals of Leicester NHS Trust and Leicestershire CCGs.
Denosumab (XGEVA®) is a drug which is injected into patients to prevent fractures where cancer has spread to the bone. Currently it’s mainly provided in hospitals, but with support from EMAHSN this project brings the therapy into the community making it much more convenient for patients as well as saving money for the NHS. EMAHSN will support regional CCGs to implement this in a community setting.